Used in the treatment of chronic hepatitis B, Bocidelpar functions as a capsid assembly modulator, disrupting the formation of the viral capsid and thereby inhibiting viral replication. It is designed to reduce the levels of hepatitis B surface antigen (HBsAg) and viral DNA in infected individuals, aiming for a functional cure. The compound is typically administered orally and is being studied in combination with other antiviral agents to enhance efficacy. Its mechanism supports immune control restoration by lowering antigen load, making it a key candidate in modern HBV therapeutic strategies.